BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech
11-Jan-2022 -
BioNTech SE and Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other ...
BioNTech
cancer
immunotherapies
+1